Maternal Probiotic Intervention to Improve Gut Health - Trial II - Burkina Faso (MPIGH-II)

NCT ID: NCT07134790

Last Updated: 2025-11-17

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 144 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-30
• Study Completion Date: 2027-06-07

Brief Summary

Burden: Environmental Enteric Dysfunction (EED) is an enteropathic condition characterized by altered gut permeability, infiltration of immune cells and changes in villous architecture and cell differentiation. EED is a major reason of malnourishment, poor neurological development, stunting, oral vaccine failure, and infection. It is believed that EED is responsible for 40% of all childhood stunting.

Knowledge gap: To date the focus of research on childhood stunting has been on the young child. It is increasingly appreciated, however, that stunting often begins in utero and the focus has shifted to women's health and pregnancy. Results from rural Bangladesh reveal poor gestational weight gain that ultimately leads to intrauterine growth restriction, low birth weight and ultimately stunting and wasting. Another study recently completed in slum settlements of Dhaka, Bangladesh demonstrated a high prevalence of EED among undernourished women. Intestinal histopathology was abnormal in more than 80% of women. We postulate that growth retardation in utero is a consequence of EED in the mother during pregnancy and lactation. This leads to systemic inflammation, which lead to disadvantageous partitioning of nutrients, and reduced nutrient availability.

Relevance: This trial will explore the conceptual framework that a probiotic or live biotherapeutic product that can improve the composition of gut microbiota, can also displace enteropathogens and reduce biomarkers of intestinal inflammation to promote gut health. This will restore healthy microbial signaling to the host epithelium, ameliorate barrier function through secretion of mucus and antimicrobial factors, and improve nutrient availability.

Objectives: The primary objective is to assess if administration of oral vancomycin followed by VE818 to pregnant women colonized with at least 2 out of 11 selected bacterial enteropathogens results in a significant change in the mean count of these organisms between the baseline and 2 weeks after completion of the intervention (Study Day 35d +2), compared to oral vancomycin followed by placebo.

Methods: Pregnant women will be recruited in antenatal clinics and in the community in Matlab in Bangladesh, Bobo-Dioulasso in Burkina Faso, Matiari in Pakistan, and Lusaka in Zambia. Study population will be women aged 18 years or older in the first trimester or early second trimester of pregnancy. Study procedures will be explained in detail and written consent will be taken before enrollment. Those women who give consent to participation will undergo a screening process which will check if any exclusion criteria are fulfilled. After consent and screening they will be randomized into either of the three arms: intervention arm (oral vancomycin followed by VE818), placebo-control arm (oral vancomycin followed by placebo), or observation-only arm. The allocation sequence will be generated by the trial statistician using a code with block permutation. The participant will remain free to withdraw at any time from the trial without giving reasons and without prejudicing her further treatment. Biological samples, including blood, saliva, urine, stool, vaginal swab, and intestinal luminal contents through CapScan. CapScan is a non-invasive device (capsule) that collects gastrointestinal samples along the gastrointestinal tract following ingestion and passes into stool.

Outcome measures/variables: The primary endpoint is the change in the mean count in the number of 11 selected fecal bacterial pathogen groups present between baseline and 2 weeks after completion of the 14-day course with Placebo or VE818 (Study arms 2 and 3), which corresponds to 35th day, +2 from the first dose of oral vancomycin.

The 11 enteropathogen targets will be detected by customized real-time quantitative PCR-based TaqMan Array Cards (TAC-qPCR) and include the following organisms: Aeromonas, Campylobacter coli, Campylobacter jejuni, Campylobacter Pan, Enteroaggregative Escherichia coli (E. coli), Enteropathogenic E. coli, Enterotoxigenic E. coli, Plesiomonas, Shigella_Enteroinvasive E. coli (EIEC), Salmonella and Klebsiella pneumoniae.

Detailed Description

Across the site, pregnant women will be screened for eligibility in their first or early second trimester of pregnancy (13-17 weeks of GA) and will be enrolled and randomized into three arms (48 women per arm). Participants will be dosed depending on the randomized arm.

As per WHO recommendations, participants in all 3 arms will receive Multiple Micronutrient Supplements (MMS) as part of routine antenatal care, which they will begin taking at enrollment and continue throughout pregnancy.

Blinding will be implemented for the comparison between the Treatment arm and the Placebo arm. However, it is not feasible to apply blinding to the Observation-only arm as the participants in this group will receive no intervention and the arm solely serves as an observational arm.

After the end of the intervention, pregnant women will be followed up until birth to record birth and pregnancy outcomes. Mother-infant dyads will be sampled 7 days after birth. Maternal and Infant health outcomes will be followed up to 1 month after childbirth to record clinical outcomes during this period.

Conditions

Environmental Enteric Dysfunction (EED)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Observation only arm

Group Type: NO_INTERVENTION

No interventions assigned to this group

Oral vancomycin + placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Enteric capsules filled with approximately 400mg of microcrystalline cellulose (bulking agent)

Oral Vancomycin

Intervention Type: DRUG

Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation

Oral vancomycin + VE818

Group Type: ACTIVE_COMPARATOR

VE818

Intervention Type: DRUG

VE818, is an 11-strain bacterial consortium rationally designed by Vedanta Biosciences Inc., to displace enteropathogens and reduce intestinal inflammation in pregnant women

Oral Vancomycin

Intervention Type: DRUG

Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation

Interventions

VE818

VE818, is an 11-strain bacterial consortium rationally designed by Vedanta Biosciences Inc., to displace enteropathogens and reduce intestinal inflammation in pregnant women

Intervention Type: DRUG

Placebo

Enteric capsules filled with approximately 400mg of microcrystalline cellulose (bulking agent)

Intervention Type: DRUG

Oral Vancomycin

Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Women aged 18 years or older in their first or early second trimester of pregnancy (13-17 weeks of gestational age [GA]), living in defined geographical areas of Bangladesh (Matlab), Pakistan, Zambia, and Burkina Faso, where it can be assumed that environmental enteropathy is prevalent

AND

2. Presence of any 2 out of 11 selected bacterial pathogen targets (Aeromonas, Campylobacter coli, Campylobacter jejuni, Campylobacter Pan, Enteroaggregative Escherichia coli, Enteropathogenic Escherichia coli, Enterotoxigenic Escherichia coli, Plesiomonas, Shigella_EIEC, Salmonella and Klebsiella pneumoniae in fecal samples measured by TAC-qPCR.

AND

3. Presence of any of the following WASH conditions -

1. use surface water, unimproved water, or limited water for drinking; OR 2. use surface water, unimproved water, or limited water for cooking; OR 3. use surface water, unimproved water, or limited water for washing utensils; OR 4. practice open defecation, use unimproved sanitation (toilet facility), or limited sanitation (toilet facility); OR 5. lack facility or have limited facility for handwashing

Exclusion Criteria

Potential participants will not be enrolled if they:

1. have MUAC ≥30 cm

2. are carrying more than one fetus (i.e., multiple pregnancy)

3. have diarrhea, defined as the passage of three or more loose stools per 24 hours, or have had diarrhea in the preceding 14 days

4. have fever or an active infection

5. have taken antibiotics or probiotics in the preceding 14 days

6. have taken steroids or non-steroidal anti-inflammatory drugs in the preceding 14 days

7. have severe anemia as determined using finger stick Hb < 8 g/dl

8. have a history of chronic digestive disease

9. have any gastrointestinal contraindication to ingestion of a capsule (known or suspected gastrointestinal obstruction, stricture, fistula, gastroparesis, or any swallowing disorder)

10. have known immunocompromised status (known history of HIV infection, autoimmune disease, diabetes mellitus, etc.)

11. have known drug hypersensitivity/allergy/intolerance

12. have chronic disease or any other illness or condition which in the opinion of the investigator will complicate the assessment of safety or efficacy

13. are medically disqualified: Any potential participant who is deemed medically unfit for trial enrollment by a non-study healthcare provider, due to the presence of severe or unstable health conditions that could compromise safety or interfere with the study outcomes, will be excluded from participation

14. have a plan to observe fast any time during the intervention period

15. have a plan to leave the study area within the follow-up period

16. are participating in any other interventional trial

17. belong to a household from which another woman is already enrolled in the study

but may be enrolled if/when these disqualifiers have expired.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Institut de Recherche en Sciences de la Santé (IRSS)

UNKNOWN

Sponsor Role: collaborator

Agence de Formation, de Recherche & d'Expertise en Santé pour l'Afrique (AFRICSanté)

UNKNOWN

Sponsor Role: collaborator

Bill and Melinda Gates Foundation

OTHER

Sponsor Role: collaborator

University Ghent

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Trenton M. Dailey-Chwalibóg, M.P.H., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Ghent University and Agence de Formation de Recherche et d'Expertise en Santé pour l'Afrique (AFRICSanté)

Laéticia C. Toé, M.D., M.Sc.

Role: PRINCIPAL_INVESTIGATOR

Ghent University and Institut de Recherche en Sciences de la Santé (IRSS), Direction Régionale de l'Ouest (DRO)

Carl Lachat, M.Eng., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University Ghent

Locations

Agence de Formation de Recherche et d'Expertise en Santé pour l'Afrique

Bobo-Dioulasso, , Burkina Faso

Site Status: RECRUITING

Countries

Burkina Faso

Central Contacts

Trenton M. Dailey-Chwalibóg, M.P.H., Ph.D

Role: CONTACT

trenton.daileychwalibog@ugent.be

+32 9 264 61 80

Laéticia C. Toé, M.D., M.Sc.

Role: CONTACT

laeticiaceline.toe@ugent.be

+32 9 264 61 80

Facility Contacts

Cheick A Ouattara, MD, PhD

Role: primary

Cheick@AhmedOuattara.onmicrosoft.com

Other Identifiers

INV-065810

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

INV-065814

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2025/033/MS/MESRI/CERS

Identifier Type: REGISTRY

Identifier Source: secondary_id

2025/0568/MS/SG/ANRP/DHEC/SEC

Identifier Type: REGISTRY

Identifier Source: secondary_id

ONZ-2024-0429

Identifier Type: -

Identifier Source: org_study_id